ADMA
NASDAQ · Biotechnology
Adma Biologics Inc
$9.63
-1.70 (-15.00%)
Financial Highlights (FY 2026)
Revenue
408.22M
Net Income
189.21M
Gross Margin
51.5%
Profit Margin
46.4%
Rev Growth
+74.0%
D/E Ratio
0.21
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 51.5% | 51.5% | 49.6% | 49.6% |
| Operating Margin | 32.3% | 29.1% | -9.0% | -9.9% |
| Profit Margin | 46.4% | 44.0% | -10.4% | -8.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 408.22M | 234.55M | 922.90M | 1.03B |
| Gross Profit | 210.15M | 120.75M | 457.58M | 508.40M |
| Operating Income | 131.85M | 68.18M | -82,955,088 | -101,708,220 |
| Net Income | 189.21M | 97.85M | -95,808,796 | -87,264,834 |
| Gross Margin | 51.5% | 51.5% | 49.6% | 49.6% |
| Operating Margin | 32.3% | 29.1% | -9.0% | -9.9% |
| Profit Margin | 46.4% | 44.0% | -10.4% | -8.5% |
| Rev Growth | +74.0% | +74.0% | +20.1% | +10.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 328.97M | 328.97M | 1.56B | 1.50B |
| Total Equity | 1.59B | 1.59B | 2.42B | 2.53B |
| D/E Ratio | 0.21 | 0.21 | 0.64 | 0.59 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 132.03M | 72.07M | -107,012,515 | -125,992,506 |
| Free Cash Flow | — | — | -83,155,340 | -96,884,239 |